文献速递银屑病与炎症性皮肤病

古塞奇尤单抗治疗乌司奴单抗应答不佳银屑病患者的真实世界有效性与安全性:一项104周多中心回顾性研究—IL PSO(意大利银屑病全景研究)

Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-02-08

这项104周多中心回顾性研究纳入14个意大利中心233例对乌司奴单抗应答不佳的中重度斑块状银屑病成人患者,评估换用古塞奇尤单抗的真实世界有效性与安全性。第52周PASI 75达89.88%、PASI 90达71.43%、PASI 100达58.83%、绝对PASI≤2达90.48%,第104周结果相似;与NAVIGATE试验相比观察到更高的PASI 75/90/100应答率。研究期间未报告显著安全性发现。

要点

  • 第52周PASI 75达89.88%、PASI 90达71.43%、PASI 100达58.83%、绝对PASI≤2达90.48%。
  • 第16周累及难治部位者达到PASI90和PASI100的可能性显著更低。
  • 肥胖患者第52周PASI75和PASI≤2应答率显著更低;第104周各亚组应答相当。

核心结论

  • 数据提示,在真实临床实践中,古塞奇尤单抗用于对乌司奴单抗应答不佳的斑块状银屑病患者,其疗效与NAVIGATE研究相当,且第16、52和104周达到PASI90和PASI100的患者百分比更高。

研究设计与样本

  • 104周多中心回顾性研究,纳入14个意大利中心的233例中重度斑块状银屑病成人患者,均在乌司奴单抗治疗失败后接受古塞奇尤单抗治疗。
  • 记录基线及第16、52、104周就诊时的患者特征和PASI评分,并统计相较基线的PASI 75、PASI 90和PASI 100改善率。

主要发现

  • 第52周PASI 75达89.88%、PASI 90达71.43%、PASI 100达58.83%、绝对PASI≤2达90.48%;第104周观察到相似的有效性结果。
  • 与NAVIGATE试验相比,观察到更高的PASI 75/90/100应答率。
  • 第16周,累及难治部位的患者达到PASI90和PASI100的可能性显著更低。
  • 第52周,肥胖患者PASI75和PASI≤2应答率显著更低。
  • 第104周,无论BMI状态、难治部位受累、心脏代谢共病及合并银屑病关节炎,各患者亚组应答相当;整个研究期间未报告显著安全性发现。

关键数值与推荐

  • 第52周PASI 75为89.88%、PASI 90为71.43%、PASI 100为58.83%、绝对PASI≤2为90.48%。
  • 第104周有效性结果与第52周相似。
  • 与NAVIGATE试验相比,PASI 75/90/100应答率更高。
  • 第16周累及难治部位者达到PASI90和PASI100的可能性显著更低;第52周肥胖患者PASI75和PASI≤2应答率显著更低。
  • 第104周各亚组(BMI状态、难治部位受累、心脏代谢共病、合并银屑病关节炎)应答相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guselkumab is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. [Correction added on [28-02-2023], after first online publication: 'humanized monoclonal antibody' has been changed to 'fully human monoclonal antibody' in the preceding sentence.] OBJECTIVES: We conducted a 104-week multicenter retrospective study to assess the effectiveness and safety of guselkumab in patients affected by plaque psoriasis with an inadequate response to ustekinumab in a real-life setting. METHODS: Our retrospective study included 233 adults affected by moderate-to-severe plaque psoriasis, enrolled in 14 different Italian centres, and treated with guselkumab after failing therapy with ustekinumab. Patient characteristics and PASI (Psoriasis Area and Severity Index) score at each visit (baseline, weeks 16, 52 and 104) were recorded. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI, compared with baseline, were registered. RESULTS: At week 52, PASI 75 was reached by 89.88% of patients, PASI 90 by 71.43%, PASI 100 by 58.83% and absolute PASI ≤2 by 90.48%. At week 104, similar effectiveness results were observed. Compared to the NAVIGATE trial, we observed higher rates of PASI 75/90/100. Patients with the involvement of difficult-to-treat areas were significantly less likely to achieve PASI90 and PASI100 at week 16. Obese patients had significantly lower rates of PASI75 and PASI ≤2 at week 52. At week 104, comparable responses were observed among all patients' subgroups, regardless of BMI status, involvement of difficult-to-treat areas, presence of cardiometabolic comorbidities and concomitant psoriatic arthritis. No significant safety findings were reported throughout the study. CONCLUSION: Our data suggest that the efficacy of guselkumab in patients with inadequate response to ustekinumab for plaque psoriasis in 'real-life' clinical practice is comparable with NAVIGATE study with higher percentages of patients achieving PASI90 and PASI100 at weeks 16, 52 and 104.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gargiulo L, Ibba L, Malagoli P, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2023. PMID: 36695061. doi:10.1111/jdv.18913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。